Belluscura PLC Belluscura appoints Senior VP of Global Sales

TIDMBELL

Belluscura PLC

16 January 2023

16 January 2023

Belluscura plc

("Belluscura" or the "Company")

Belluscura appoints Senior Vice President of Global Sales

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Robert ("Bob") Fary has joined the Company as Senior Vice President of Global Sales.

Bob has thirty-years of experience in the respiratory industry where he has held leadership roles at major oxygen concentrator manufacturers and durable medical equipment companies. During the past two decades, Bob's industry leading team was directly responsible or contributed to the sale of over 1 million portable oxygen concentrators ("POCs"), generating revenues in excess of $1 billion.

Commenting on the hire, Robert Rauker, Chief Executive Officer, Belluscura plc, said:

"We are very excited that Bob has joined our team as we enter the next stage of growth at Belluscura. His deep knowledge of the portable oxygen concentrator sector and its channels to market will be invaluable as we build on our success to date to bring our latest generation of POCs to market."

Bob Fary, Senior Vice President of Global Sales, commented:

"I am delighted to have joined Belluscura at this important juncture for the Company as it captures the demand in its markets for its best-in-class products. The planned launch of DISCOV-R will be another exciting step in meeting the needs of patients around the world. I look forward to working alongside the wider executive team to grow the Company's sales in the US and beyond."

ENDS

For further information, please contact:

 
 Belluscura plc                       www.belluscura.com 
 Robert Rauker, Chief Executive       via MHP 
  Officer 
 Anthony Dyer, Chief Financial 
  Officer 
 
 SPARK Advisory Partners Limited      Tel: [phone] 
  (NOMAD) 
 Neil Baldwin 
 
 Dowgate Capital Limited (Broker)     Tel: [phone] 
 James Serjeant / Nicholas Chambers 
 
 MHP (Financial PR and Investor       Tel: [phone] 
  Relations) 
 Katie Hunt / Pete Lambie / Matthew   Email: [e-mail] 
  Taylor 
 
 
   About Belluscura plc   (   www.belluscura.com   ) 

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

About RNS Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAPFSFDFDEFA

(END) Dow Jones Newswires

January 16, 2023 02:00 ET (07:00 GMT)